Palatin Technologies (PTN) Shares Outstanding (2010 - 2026)
Palatin Technologies' (PTN) quarterly Shares Outstanding (Entity) came in at $3.9 million in Q1 2026, up 642.46% YoY from $526891.0 in Q1 2025, and up 54.04% on a QoQ basis from $2.5 million in Q4 2025.
Palatin Technologies (PTN) Shares Outstanding (2010 - 2026) Analysis & Trends
Palatin Technologies (PTN) has 17 years of Shares Outstanding (Entity) data on file, last reported at $3.9 million in Q1 2026.
- Quarterly Shares Outstanding (Entity) rose 642.46% year-over-year to $3.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.9 million (up 642.46% YoY) and the FY2025 annual result came in at $929597.0, up 216.25% from the prior year.
- Shares Outstanding (Entity) rose to $3.9 million in Q1 2026, from $2.5 million in the prior quarter.
- In the past five years, Shares Outstanding (Entity) ranged from a high of $3.9 million in Q1 2026 to a low of $185419.0 in Q1 2022.
- A 5-year average of $708975.8 and a median of $293942.0 in 2024 frame the typical range for Shares Outstanding (Entity).
- Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) advanced 0.42% — and 2026, when it jumped 642.46%.
- Tracing PTN's Shares Outstanding (Entity) over 5 years: stood at $207090.0 in 2022, then soared by 38.15% to $286103.0 in 2023, then jumped by 44.25% to $412698.0 in 2024, then jumped by 515.37% to $2.5 million in 2025, then soared by 54.04% to $3.9 million in 2026.
- The last three Shares Outstanding (Entity) figures came in at $3.9 million (Q1 2026), $2.5 million (Q4 2025), and $973291.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Palatin Technologies | 40.37 Mn | 40.37 Mn | - | 3.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.91 Mn |
| Dec 31, 2025 | 2.54 Mn |
| Sep 30, 2025 | 971,650.00 |
| Jun 30, 2025 | 828,978.00 |
| Mar 31, 2025 | 526,891.00 |
| Dec 31, 2024 | 412,698.00 |
| Sep 30, 2024 | 396,902.00 |
| Jun 30, 2024 | 293,942.00 |
| Mar 31, 2024 | 315,848.00 |
| Dec 31, 2023 | 281,955.00 |
| Sep 30, 2023 | 243,414.00 |
| Jun 30, 2023 | 217,803.00 |
| Mar 31, 2023 | 228,648.00 |
| Dec 31, 2022 | 216,057.00 |
| Sep 30, 2022 | 192,694.00 |
| Jun 30, 2022 | 190,875.00 |
| Mar 31, 2022 | 191,044.00 |
| Dec 31, 2021 | 190,621.00 |
| Sep 30, 2021 | 190,586.00 |
| Jun 30, 2021 | 189,320.00 |